Clinical Efficacy and Tolerability of Cimicoxib in Dogs with Osteoarthritis: A Multicentre Prospective Study

Joanna Murrell, Erik Grandemange, Frederique Woehrle, Julie Menard, Kate White

School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK.
School of Veterinary Sciences, University of Bristol, Bristol, UK.
Vetoquinol S.A., Centre de Recherche, Lure, France.
Vétoquinol S.A., Centre de Recherche, Lure, France.
Vétoquinol S.A., Paris, France.

DOI: 10.4236/ojvm.2014.45010                

Abstract

Background: Cimicoxib is a coxib recently licensed in Europe for pain and inflammation associated with osteoarthritis (OA), and the management of perioperative pain due to orthopaedic or soft tissue surgery. Purpose: This prospective study was to complete the product information for the end users by providing additional scientific data obtained after a thirty-day treatment course of cimicoxib in dogs with OA, and to collect owners’ feedback. Data were collected from nine European countries with 492 client owned dogs recruited to the trial. Dogs were treated once daily with 2 mg/kg cimicoxib orally. Immediately before, at Day (D) 15 and D30 after the start of treatment veterinarians and owners scored body condition, appetite, locomotion, lameness, pain on palpation and manipulation of the joint and joint effusion (veterinarians) and dog demeanor and well being (owners). In a subset of dogs, serum urea (n = 191), creatinine (n = 184), AST (n = 141) and ALT (n = 174) were measured at day (D) 0 and D30. Statistical tests were carried out to detect significant changes in the clinical parameters with time. Results and Discussion: Veterinary and owner assessments were analysed from 236 and 215 dogs respectively. Improvements in locomotion, mobility, pain scores and dog demeanor and body condition were identified; outcome measures assessed by veterinarians continued to improve after 15 days of treatment up to the 30-day time point. At D30 a significantly higher number of dogs had an urea concentration superior to the upper limit of the reference range. However, there was no significant difference for creatinine, ALT and AST. Conclusions: A 30-day treatment course with cimicoxib improved locomotion and decreased pain scores in dogs with OA, with minimal adverse effects. These data, support pre-clinical data in dogs receiving cimicoxib and are useful for veterinarians making decisions about which NSAID to administer to dogs that require pain management for OA.

Keywords

Osteoarthritis, Dogs, NSAID, Cimicoxib, Pain, Analgesia, Owner, Kidney, Renal, Mobility

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Johnston, S.A. and Budsberg, S.C. (1997) Nonsteroidal Anti-Inflammatory Drugs and Corticosteroids for the Management of Canine Osteoarthritis. Veterinary Clinics of North America: Small Animal Practice, 27, 841-862.
[2]	Marshall, W., Bockstahle, B., Hulse, D. and Carmicheal, S. (2009) A Review of Osteoarthritis and Obesity: Current Understanding of the Relationship and Benefit of Obesity Treatment and Prevention in the Dog. Veterinary and Comparative Orthopaedics and Traumatology, 22, 339-345.
[3]	Kukanich, B., Bidgood, T. and Knesl, O. (2012) Clinical Pharmacology of Nonsteroidal Anti-Inflammatory Drugs in Dogs. Veterinary Anaesthesia and Analgesia, 39, 69-90. http://dx.doi.org/10.1111/j.1467-2995.2011.00675.x
[4]	Henrotin, Y., Sanchez, C. and Balligand, M. (2005) Pharmaceutical and Nutraceutical Management of Canine Osteoarthritis: Present and Future Perspectives. The Veterinary Journal, 170, 113-123. http://dx.doi.org/10.1016/j.tvjl.2004.08.014
[5]	Hercock, C.A., Pinchbeck, G., Giejda, A., Clegg, P.D. and Innes, J.F. (2009) Validation of a Client-Based Clinical Metrology Instrument for the Evaluation of Canine Elbow Osteoarthritis. Journal of Small Animal Practice, 50, 266-271. http://dx.doi.org/10.1111/j.1748-5827.2009.00765.x
[6]	EMA EPAR 2011 Cimalgex. European Public Assessment Report. London.
[7]	(2012) IRIS Staging of CKD. http://www.iris-kidney.com/guidelines/en/staging_ckd.shtml
[8]	Autefage, A., Palissier, F.M., Asimus, E. and Pepin-Richard, C. (2011) Long-Term Efficacy and Safety of Firocoxib in the Treatment of Dogs with Osteoarthritis. Veterinary Record, 168, 617-621. http://dx.doi.org/10.1136/vr.d1456
[9]	Bath, P.M., Macleod, M.R. and Green, A.R. (2009) Emulating Multicentre Clinical Stroke Trials: A New Paradigm for Studying Novel Interventions in Experimental Models of Stroke. International Journal of Stroke, 4, 471-479. http://dx.doi.org/10.1111/j.1747-4949.2009.00386.x
[10]	Mansa, S., Palmer, E., Grøndahl, C., Lønaas, L. and Nyman, G. (2007) Long-Term Treatment with Carprofen of 805 Dogs with Osteoarthritis. Veterinary Record, 160, 427-430. http://dx.doi.org/10.1136/vr.160.13.427
[11]	Edamura, K., King, J.N., Seewald, W., Sakakibara, N. and Okumura, M. (2012) Comparison of Oral Robenacoxib and Carprofen for the Treatment of Osteoarthritis in Dogs: A Randomized Clinical Trial. The Journal of Veterinary Medical Science, 74, 1121-1131. http://dx.doi.org/10.1292/jvms.11-0529
[12]	Holton, L.L., Scott, E.M., Nolan, A.M., Welsh, E. and Flaherty, D. (1998) Comparison of Three Methods Used for Assessment of Pain in Dogs. Journal of the American Veterinary Medical Association, 212, 61-66.
[13]	Hielm-Bjorkman, A.K., Kapatkin, A.S. and Rita, H.J. (2011) Reliability and Validity of a Visual Analogue Scale Used by Owners to Measure Chronic Pain Attributable to Osteoarthritis in Their Dogs. American Journal of Veterinary Research, 72, 601-607. http://dx.doi.org/10.2460/ajvr.72.5.601
[14]	Hielm-bjorkman, A.K., Kuusela, E., Liman, A., Markkola, A., Saarto, E., Huttunen, P., Leppaluoto, J., Tulamo, R.M. and Raekalio, M. (2003) Evaluation of Methods for Assessment of Pain Associated with Chronic Osteoarthritis in Dogs. Journal of the American Veterinary Medical Association, 222, 1552-1558. http://dx.doi.org/10.2460/javma.2003.222.1552
[15]	Brown, D.C., Boston, R., Coyne, J.C. and Farrar, J.T. (2008) Ability of the Canine Brief Pain Inventory to Detect Response to Treatment in Dogs with Osteoarthritis. Journal of the American Veterinary Medical Association, 233, 1278-1283. http://dx.doi.org/10.2460/javma.233.8.1278
[16]	Hudson, J.T., Slater, M.R., Taylor, L., Scott, H.M. and Kerwin, S.C. (2004) Assessing Repeatability and Validity of a Visual Analogue Scale Questionnaire for Use in Assessing Pain and Lameness in Dogs. American Journal of Veterinary Research, 65, 1634-1643. http://dx.doi.org/10.2460/ajvr.2004.65.1634
[17]	Wiseman-Orr, M.L., Scott, E.M., Reid, J. and Nolan, A.M. (2006) Validation of a Structured Questionnaire as an Instrument to Measure Chronic Pain in Dogs on the Basis of Effects on Health-Related Quality of Life. American Journal of Veterinary Research, 67, 1826-1836. http://dx.doi.org/10.2460/ajvr.67.11.1826
[18]	Rao, P. and Knaus, E.E. (2008) Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. Journal of Pharmacy & Pharmaceutical Sciences, 11, 81s-110s.
[19]	Burian, M. and Geisslinger, G. (2005) Cox-Dependent Mechanisms Involved in the Antinociceptive Action of NSAIDs at Central and Peripheral Sites. Pharmacology & Therapeutics, 107, 139-154. http://dx.doi.org/10.1016/j.pharmthera.2005.02.004
[20]	Innes, J.F., Clayton, J. and Lascelles, B.D.X. (2010) Review of the Safety and Efficacy of Long-Term NSAID Use in the Treatment of Canine Osteoarthritis. Veterinary Record, 166, 226-230. http://dx.doi.org/10.1136/vr.c97
[21]	Strand, V., Simon, L.S., Dougados, M., Sands, G.H., Bhadra, P., Breanza, A. and Immitt, J. (2011) Treatment of Osteoarthritis with Continuous versus Intermittent Celecoxib. Journal of Rheumatology, 38, 2625-2634. http://dx.doi.org/10.3899/jrheum.110636
[22]	Wiseman-Orr, M.L., Nolan, A.M., Reid, J. and Scott, E.M. (2004) Development of a Questionnaire to Measure the Effects of Chronic Pain on Health-Related Quality of Life in Dogs. American Journal of Veterinary Research, 65, 1077-1084. http://dx.doi.org/10.2460/ajvr.2004.65.1077
[23]	Hielm-bjorkman, A.K., Rita, H. and Tulamo, R.M. (2009) Psychometric Testing of the Helsinki Chronic Pain Index by Completion of a Questionnaire in Finnish by Owners of Dogs with Chronic Signs of Pain Caused by Osteoarthritis. American Journal of Veterinary Research, 70, 727-734. http://dx.doi.org/10.2460/ajvr.70.6.727
[24]	Innes, J.F. and Barr, A.R. (1998) Can Owners Assess Outcome Following Treatment of Canine Cruciate Ligament Deficiency? Journal of Small Animal Practice, 39, 373-378. http://dx.doi.org/10.1111/j.1748-5827.1998.tb03735.x
[25]	Papich, M.G. (2008) An Update on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Small Animals. Veterinary Clinics of North America: Small Animal Practice, 38, 1243-1266. http://dx.doi.org/10.1016/j.cvsm.2008.09.002
[26]	Reymond, N., Speranza, C., Gruet, P., Seewald, W. and King, J.N. (2011) Robenacoxib vs. Carprofen for the Treatment of Canine Osteoarthritis; A Randomized, Noninferiority Clinical Trial. Journal of Veterinary Pharmacology and Therapeutics, 35, 175-183. http://dx.doi.org/10.1111/j.1365-2885.2011.01297.x
[27]	Vesterinen, H.V., Egan, K., Deister, A., Schlattmann, P., Macleod, M.R. and Dirnagl, U. (2011) Systematic Survey of the Design, Statistical Analysis, and Reporting of Studies Published in the 2008 Volume of the Journal of Cerebral Blood Flow and Metabolism. Journal of Cerebral Blood Flow & Metabolism, 31, 1064-1072. http://dx.doi.org/10.1038/jcbfm.2010.217
[28]	Dirnagl, U. and Macleod, M.R. (2009) Stroke Research at a Road Block: The Streets from Adversity Should Be Paved with Meta-Analysis and Good Laboratory Practice. British Journal of Pharmacology, 157, 1154-1156. http://dx.doi.org/10.1111/j.1476-5381.2009.00211.x
[29]	Lascelles, B.D., Hansen, B.D., Roe, S., Depuy, V., Thomson, A., Pierce, C.C., Smith, E.S. and Rowinski, E. (2007) Evaluation of Client-Specific Outcome Measures and Activity Monitoring to Measure Pain Relief in Cats with Osteoarthritis. Journal of Veterinary Internal Medicine, 21, 410-416. http://dx.doi.org/10.1111/j.1939-1676.2007.tb02983.x
[30]	Malek, S., Sample, S.J., Schwartz, Z., Nemke, B., Jacobson, P.B., Cozzi, E.M., Schaefer, S.L., Bleedorn, J.A., Holzman, G. and Muir, P. (2012) Effect of Analgesic Therapy on Clinical Outcome Measures in a Randomized Controlled Trial Using Client-Owned Dogs with Hip Osteoarthritis. BMC Veterinary Research, 8, 185. http://dx.doi.org/10.1186/1746-6148-8-185
[31]	Conzemius, M.G. and Evans, R.B. (2012) Caregiver Placebo Effect for Dogs with Lameness from Osteoarthritis. Journal of the American Veterinary Medical Association, 241, 1314-1319. http://dx.doi.org/10.2460/javma.241.10.1314
[32]	Budsberg, S.C., Johnston, S.A., Schwarz, P.D., Decamp, C.E. and Claxton, R. (1999) Efficacy of Etodolac for the Treatment of Osteoarthritis of the Hip Joints in Dogs. Journal of the American Veterinary Medical Association, 214, 206-210.
[33]	Ryan, W.G., Moldave, K. and Carithers, D. (2007) Clinical Effectiveness and Safety of a New NSAID, Firocoxib: A 1,000 Dog Study. Veterinary Therapeutics, 7, 119-126.
[34]	Concordet, D., Vergez, F., Trumel, C., Diquelou, A., lanore, D., Le Garrerès, A., Pagès, J.P., Pechereau, D., Medaille, C. and Braun, J.P. (2008) A Multicentric Retrospective Study of Serum/Plasma Urea and Creatinine Concentrations in Dogs Using Univariate and Multivariate Decision Rules to Evaluate Diagnostic Efficiency. Veterinary Clinical Pathology, 37, 96-103. http://dx.doi.org/10.1111/j.1939-165X.2008.00007.x
[35]	Ulleberg, T., Robben, J., Nordahl, K.M., Ulleberg, T. and Heiene, R. (2011) Plasma Creatinine in Dogs: Intra- and Inter-Laboratory Variation in 10 European Veterinary Laboratories. Acta Veterinaria Scandinavica, 53, 25. http://dx.doi.org/10.1186/1751-0147-53-25
[36]	Hosten, A.O. (1990) BUN and Creatinine in Clinical Methods. In: Walker, H.K., Hall, W.D. and Hurst, J.W., Eds., The History, Physical, and Laboratory Examinations, 3rd Edition, Butterworths, Boston, 874-878.
[37]	Williams, V.M., Lascelles, B.D. and Robson, M.C. (2005) Current Attitudes to, and Use of, Peri-Operative Analgesia in Dogs and Cats by Veterinarians in New Zealand. New Zealand Veterinary Journal, 53, 193-202. http://dx.doi.org/10.1080/00480169.2005.36504